BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Piester T, Frymoyer A, Christofferson M, Yu H, Bass D, Park KT. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24:227-34. [PMID: 29361094 DOI: 10.1093/ibd/izx037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Papamichael K, Cheifetz AS. Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies. Expert Opinion on Drug Metabolism & Toxicology. [DOI: 10.1080/17425255.2021.2027367] [Reference Citation Analysis]
2 Giráldez-Montero JM, Gonzalez-Lopez J, Campos-Toimil M, Lamas-Díaz MJ. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease: Limits and improvements. Br J Clin Pharmacol 2021;87:2216-27. [PMID: 33197071 DOI: 10.1111/bcp.14654] [Reference Citation Analysis]
3 Chang HP, Shakhnovich V, Frymoyer A, Funk RS, Becker ML, Park KT, Shah DK. A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab. Br J Clin Pharmacol 2021. [PMID: 34189743 DOI: 10.1111/bcp.14963] [Reference Citation Analysis]
4 Zijlstra M, Jongsma MME, de Vries A, Schaap T, Bloem K, de Ridder L. Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric Inflammatory Bowel Disease Patients. J Pediatr Gastroenterol Nutr 2021;72:56-60. [PMID: 32804907 DOI: 10.1097/MPG.0000000000002906] [Reference Citation Analysis]